Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Request a FREE Sample of our FcRn Binding Kit!
Request a FREE Sample of our Fc gamma RI / CD64 Binding Kit !
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| ENN-C5128 | SARS-CoV-2 | SARS-CoV-2 (COVID-19) Envelope protein, GST,His Tag |  |
|
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Tecovirimat | SIGA-246; ST-246 | Approved | Siga Technologies Inc | Tpoxx | United States | Smallpox | Siga Technologies Inc | 2018-07-13 | Smallpox; Cowpox; Vaccinia; Poxviridae Infections; Monkeypox | Details |
| Tecovirimat | SIGA-246; ST-246 | Approved | Siga Technologies Inc | Tpoxx | United States | Smallpox | Siga Technologies Inc | 2018-07-13 | Smallpox; Cowpox; Vaccinia; Poxviridae Infections; Monkeypox | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Targeting HIV-1 Env gp140 antibodies | Phase 2 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | HIV Infections | Details | |
| Temelimab | GNN-001; GENHP-01; GNbAC-1 | Phase 2 Clinical | Geneuro Sa | Multiple Sclerosis, Relapsing-Remitting; Diabetes Mellitus, Type 1; Multiple Sclerosis; Post-Acute COVID-19 Syndrome | Details |
| PGDM-1400 | PGDM-1400; PGDM1400LS | Phase 2 Clinical | International Aids Vaccine Initiative | HIV Infections; Acquired Immunodeficiency Syndrome; Retroviridae Infections; Sexually Transmitted Diseases, Viral; HIV Seropositivity | Details |
| VIS-513 | VIS-513; Ab-513 | Phase 1 Clinical | Otsuka Pharmaceutical Co Ltd, Serum Institute Of India Ltd, Visterra Inc | Dengue | Details |
| Targeting HIV-1 Env gp140 antibodies | Phase 2 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | HIV Infections | Details | |
| Temelimab | GNN-001; GENHP-01; GNbAC-1 | Phase 2 Clinical | Geneuro Sa | Multiple Sclerosis, Relapsing-Remitting; Diabetes Mellitus, Type 1; Multiple Sclerosis; Post-Acute COVID-19 Syndrome | Details |
| PGDM-1400 | PGDM-1400; PGDM1400LS | Phase 2 Clinical | International Aids Vaccine Initiative | HIV Infections; Acquired Immunodeficiency Syndrome; Retroviridae Infections; Sexually Transmitted Diseases, Viral; HIV Seropositivity | Details |
| VIS-513 | VIS-513; Ab-513 | Phase 1 Clinical | Otsuka Pharmaceutical Co Ltd, Serum Institute Of India Ltd, Visterra Inc | Dengue | Details |
This web search service is supported by Google Inc.
A-Z
